| Year |
Citation |
Score |
| 2024 |
Tzetzo SL, Kramer ED, Mohammadpour H, Kim M, Rosario SR, Yu H, Dolan MR, Oturkar CC, Morreale BG, Bogner PN, Stablewski AB, Benavides FJ, Brackett CM, Ebos JML, Das GM, ... ... Abrams SI, et al. Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression. Iscience. 27: 109187. PMID 38420590 DOI: 10.1016/j.isci.2024.109187 |
0.337 |
|
| 2023 |
Alvarez-Arzola R, Oliver L, Messmer MM, Twum DYF, Lee KP, Muhitch JB, Mesa C, Abrams SI. A Bacterial and Ganglioside-based Nanoparticle Initiates Reprogramming of Macrophages and Promotes Antitumor Phenotypes. Journal of Immunology (Baltimore, Md. : 1950). PMID 38117752 DOI: 10.4049/jimmunol.2300256 |
0.302 |
|
| 2023 |
McGray AJR, Chiello JL, Tsuji T, Long M, Maraszek K, Gaulin N, Rosario SR, Hess SM, Abrams SI, Kozbor D, Odunsi K, Zsiros E. BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control. Journal For Immunotherapy of Cancer. 11. PMID 37647218 DOI: 10.1136/jitc-2023-006863 |
0.423 |
|
| 2023 |
Chow J, Khan A, Gaudieri M, Wasik BJ, Conway A, Soh KT, Repasky EA, Schwaab T, Wallace PK, Abrams SI, Singh AK, Muhitch JB. Tumor and immune remodeling following radiotherapy in human renal cell carcinoma. Journal For Immunotherapy of Cancer. 11. PMID 37080610 DOI: 10.1136/jitc-2022-006392 |
0.377 |
|
| 2022 |
Dai T, Rosario SR, Katsuta E, Sawant Dessai A, Paterson EJ, Novickis AT, Cortes Gomez E, Zhu B, Liu S, Wang H, Abrams SI, Seshadri M, Bshara W, Dasgupta S. Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence. Cell Reports. 41: 111756. PMID 36476868 DOI: 10.1016/j.celrep.2022.111756 |
0.352 |
|
| 2022 |
Colligan SH, Amitrano AM, Zollo RA, Peresie J, Kramer ED, Morreale B, Barbi J, Singh PK, Yu H, Wang J, Opyrchal M, Sykes DB, Nemeth MJ, Abrams SI. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression. The Journal of Clinical Investigation. 132. PMID 36453551 DOI: 10.1172/JCI158661 |
0.42 |
|
| 2022 |
Oliver L, Alvarez R, Diaz R, Valdés A, Colligan SH, Nemeth MJ, Twum DYF, Fernández A, Fernández-Medina O, Carlson LM, Yu H, Eng KH, Hensen ML, Rábade-Chediak ML, Fernández LE, ... ... Abrams SI, et al. Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator. Journal For Immunotherapy of Cancer. 10. PMID 36150744 DOI: 10.1136/jitc-2022-004710 |
0.423 |
|
| 2022 |
Papadas A, Deb G, Cicala A, Officer A, Hope C, Pagenkopf A, Flietner E, Morrow ZT, Emmerich P, Wiesner J, Arauz G, Bansal V, Esbona K, Capitini CM, Matkowskyj KA, ... ... Abrams SI, et al. Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment. Cell Reports. 40: 111201. PMID 35977482 DOI: 10.1016/j.celrep.2022.111201 |
0.446 |
|
| 2022 |
Shen H, Zhang Y, Kramer ED, Katsuta E, Wan Y, Chen Y, Wang J, Zhang Y, Matsuzaki J, Frangou C, Abrams SI, Zhang J. Loss-of-function of the hippo transducer TAZ reduces mammary tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Gene Therapy. PMID 35840667 DOI: 10.1038/s41417-022-00502-0 |
0.492 |
|
| 2022 |
Khan ANH, Emmons TR, Magner WJ, Alqassim E, Singel KL, Ricciuti J, Eng KH, Odunsi K, Tomasi TB, Lee K, Abrams SI, Mesa C, Segal BH. VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients. Cancer Immunology, Immunotherapy : Cii. PMID 35166871 DOI: 10.1007/s00262-022-03156-x |
0.491 |
|
| 2021 |
Yokoi T, Oba T, Kajihara R, Abrams SI, Ito F. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Scientific Reports. 11: 21992. PMID 34754037 DOI: 10.1038/s41598-021-01455-4 |
0.352 |
|
| 2021 |
Patel A, Oba T, Kajihara R, Yokoi T, Abrams SI, Ito F. Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression. Journal of Immunology (Baltimore, Md. : 1950). PMID 34362833 DOI: 10.4049/jimmunol.2100281 |
0.41 |
|
| 2021 |
He X, Zhou S, Quinn B, Jahagirdar D, Ortega J, Abrams SI, Lovell JF. HPV-Associated Tumor Eradication by Vaccination with Synthetic Short Peptides and Particle-Forming Liposomes. Small (Weinheim An Der Bergstrasse, Germany). e2007165. PMID 33605054 DOI: 10.1002/smll.202007165 |
0.348 |
|
| 2021 |
Yao S, Cheng TD, Elkhanany A, Yan L, Omilian A, Abrams SI, Evans S, Hong CC, Qi Q, Davis W, Liu S, Bandera EV, Odunsi K, Takabe K, Khoury T, et al. Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T Cell Exhaustion. Journal of the National Cancer Institute. PMID 33395700 DOI: 10.1093/jnci/djaa215 |
0.358 |
|
| 2020 |
Abrams SI. Developmental pathways of myeloid-derived suppressor cells in neoplasia. Cellular Immunology. 360: 104261. PMID 33373817 DOI: 10.1016/j.cellimm.2020.104261 |
0.348 |
|
| 2020 |
Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI, Liu S, Ito F. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nature Communications. 11: 5415. PMID 33110069 DOI: 10.1038/s41467-020-19192-z |
0.36 |
|
| 2020 |
Kramer ED, Abrams SI. Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity. Frontiers in Immunology. 11: 1963. PMID 32983128 DOI: 10.3389/Fimmu.2020.01963 |
0.502 |
|
| 2020 |
Stenzel AE, Abrams SI, Joseph JM, Goode EL, Tario JD, Wallace PK, Kaur D, Adamson AK, Buas MF, Lugade AA, Laslavic A, Taylor SE, Orr B, Edwards RP, Elishaev E, et al. Circulating CD14 HLA-DR monocytic cells as a biomarker for epithelial ovarian cancer progression. American Journal of Reproductive Immunology (New York, N.Y. : 1989). e13343. PMID 32905653 DOI: 10.1111/Aji.13343 |
0.465 |
|
| 2020 |
Chow J, Hoffend NC, Abrams SI, Schwaab T, Singh AK, Muhitch JB. Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America. PMID 32900949 DOI: 10.1073/Pnas.2001933117 |
0.478 |
|
| 2020 |
Zonneville J, Colligan S, Grant S, Miller A, Wallace P, Abrams SI, Bakin AV. Blockade of p38 kinase impedes the mobilization of pro-tumorigenic myeloid populations to impact breast cancer metastasis. International Journal of Cancer. PMID 32452014 DOI: 10.1002/Ijc.33050 |
0.486 |
|
| 2020 |
Knudsen ES, Kumarasamy V, Chung S, Ruiz A, Vail P, Tzetzo S, Wu J, Nambiar R, Seshadri M, Abrams SI, Wang J, Witkiewicz AK. Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. Gut. PMID 32424005 DOI: 10.1136/Gutjnl-2020-321000 |
0.356 |
|
| 2020 |
Khan ANH, Emmons TR, Wong JT, Alqassim E, Singel KL, Mark J, Smith BE, Tario JD, Eng KH, Moysich KB, Odunsi K, Abrams SI, Segal BH. Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils. Cancer Immunology Research. PMID 32238380 DOI: 10.1158/2326-6066.Cir-19-0556 |
0.463 |
|
| 2020 |
Srivastava P, Tzetzo SL, Gomez EC, Eng KH, Jani Sait SN, Kuechle JB, Singh PK, De Jong K, Wiatrowski KR, Peresie J, Dimitroff A, Lynch ML, Wang J, Abrams SI, Griffiths EA, et al. Inhibition of LSD1 in MDS progenitors restores differentiation of CD141 conventional dendritic cells. Leukemia. PMID 32099035 DOI: 10.1038/S41375-020-0765-5 |
0.365 |
|
| 2020 |
Mammadova-Bach E, Gil-Pulido J, Sarukhanyan E, Burkard P, Shityakov S, Schonhart C, Stegner D, Remer K, Nurden P, Nurden AT, Dandekar T, Nehez L, Dank M, Braun A, Mezzano D, ... Abrams SI, et al. Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived Galectin-3. Blood. PMID 32040544 DOI: 10.1182/Blood.2019002649 |
0.431 |
|
| 2020 |
Boland PM, Muhitch J, Abrams SI, Maguire O, Minderman H, Bajor DL, Saltzman JN, Wang K, Hutson A, Mukherjee S, Iyer RV, Kalinski P, Fountzilas C. Initial correlative studies from a trial of cetuximab and pembrolizumab in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 38: 4062-4062. DOI: 10.1200/Jco.2020.38.15_Suppl.4062 |
0.399 |
|
| 2020 |
Yao S, Cheng T, Elkhanany A, Yan L, Omilian A, Abrams SI, Evans S, Hong C, Qi Q, Davis W, Liu S, Bandera EV, Odunsi K, Takabe K, Khoury T, et al. Abstract IA26: Breast tumor microenvironment in black women: A distinct signature of CD8+ T-cell exhaustion Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-Ia26 |
0.406 |
|
| 2020 |
Oba T, Keler T, Marsh HC, Abrams S, Ito F. Abstract P5-04-03: Conversion of non-T cell-inflamed triple-negative breast cancer byin situimmunomodulation of induced intratumoral cross-presenting dendritic cells Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P5-04-03 |
0.352 |
|
| 2020 |
Mohammadpour H, MacDonald CR, Qiao G, Chen M, Dong B, Hylander BL, McCarthy PL, Abrams SI, Repasky EA. Abstract P3-01-02: B2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-01-02 |
0.461 |
|
| 2019 |
Colligan SH, Tzetzo SL, Abrams SI. Myeloid-driven mechanisms as barriers to antitumor CD8 T cell activity. Molecular Immunology. 118: 165-173. PMID 31884388 DOI: 10.1016/J.Molimm.2019.12.012 |
0.479 |
|
| 2019 |
Mohammadpour H, MacDonald CR, Qiao G, Chen M, Dong B, Hylander BL, McCarthy PL, Abrams SI, Repasky EA. β2 Adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. The Journal of Clinical Investigation. PMID 31566578 DOI: 10.1172/Jci129502 |
0.364 |
|
| 2019 |
Stenzel AE, Abrams SI, Moysich KB. A Call for Epidemiological Research on Myeloid-Derived Suppressor Cells in Ovarian Cancer: A Review of the Existing Immunological Evidence and Suggestions for Moving Forward. Frontiers in Immunology. 10: 1608. PMID 31354741 DOI: 10.3389/Fimmu.2019.01608 |
0.452 |
|
| 2019 |
Mastio J, Condamine T, Dominguez G, Kossenkov AV, Donthireddy L, Veglia F, Lin C, Wang F, Fu S, Zhou J, Viatour P, Lavilla-Alonso S, Polo AT, Tcyganov EN, Mulligan C, ... ... Abrams SI, et al. Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. The Journal of Experimental Medicine. PMID 31239386 DOI: 10.1084/Jem.20181952 |
0.501 |
|
| 2019 |
Muhitch JB, Hoffend NC, Azabdaftari G, Miller A, Bshara W, Morrison CD, Schwaab T, Abrams SI. Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma. Journal For Immunotherapy of Cancer. 7: 155. PMID 31221219 DOI: 10.1186/S40425-019-0630-0 |
0.399 |
|
| 2019 |
Volz J, Mammadova-Bach E, Gil-Pulido J, Nandigama R, Remer K, Sorokin L, Zernecke A, Abrams SI, Ergün S, Henke E, Nieswandt B. Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice. Blood. PMID 30952674 DOI: 10.1182/Blood.2018877043 |
0.475 |
|
| 2019 |
Singel KL, Emmons TR, Khan ANH, Mayor PC, Shen S, Wong JT, Morrell K, Eng KH, Mark J, Bankert RB, Matsuzaki J, Koya RC, Blom AM, McLeish KR, Qu J, ... ... Abrams SI, et al. Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. Jci Insight. PMID 30730851 DOI: 10.1172/Jci.Insight.122311 |
0.543 |
|
| 2019 |
Twum DY, Colligan SH, Hoffend NC, Katsuta E, Cortes Gomez E, Hensen ML, Seshadri M, Nemeth MJ, Abrams SI. IFN regulatory factor-8 expression in macrophages governs an antimetastatic program. Jci Insight. 4. PMID 30728331 DOI: 10.1172/Jci.Insight.124267 |
0.406 |
|
| 2019 |
Yang Y, George S, Levine EG, Schwaab T, Muhitch J, Li Q, Attwood K, Groman A, Abrams SI, Kalinski P, Singh AK, Guru K, Chatta GS. Interim analysis of a pilot study: Impact of high-dose, single fraction radiation on immunogenicity of sipuleucel-T in metastatic castration resistant prostate cancer patients. Journal of Clinical Oncology. 37: e16538-e16538. DOI: 10.1200/Jco.2019.37.15_Suppl.E16538 |
0.312 |
|
| 2019 |
Yalowich JC, Kanagasabai R, Netherby CS, Messmer MN, Abrams SI. Abstract 1233: Myeloperoxidase (MPO) activity in myeloid-derived suppressor cells (MDSCs): effects on anticancer drug activity Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1233 |
0.305 |
|
| 2019 |
Bakin AV, Zonneville J, Walden R, Grant S, Colligan S, Miller A, Truskinovsky AM, Abrams S. Abstract LB-316: Suppression of tumor angiogenesis and metastasis by targeting a novel p38-driven tumor-stromal crosstalk Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-316 |
0.522 |
|
| 2019 |
Klement JD, Paschall AV, Redd PS, Ibrahim ML, Lu C, Yang D, Celis E, Abrams SI, Ozato K, Liu K. Abstract 3226: The IRF8-osteopontin-CD44 axis functions as an immune checkpoint to control CD8+ T cell activation and tumor immune evasion Cancer Research. 79: 3226-3226. DOI: 10.1158/1538-7445.Am2019-3226 |
0.555 |
|
| 2018 |
Klement JD, Paschall AV, Redd PS, Ibrahim ML, Lu C, Yang D, Celis E, Abrams SI, Ozato K, Liu K. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. The Journal of Clinical Investigation. PMID 30395540 DOI: 10.1172/Jci123360 |
0.555 |
|
| 2018 |
Orillion AR, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti HC, Elbanna M, Chintala S, Ciesielski MJ, Fontana L, Kao C, Elzey BD, Ratliff TL, Nelson DE, Smiraglia DJ, Abrams SI, et al. Dietary protein restriction reprograms tumor associated macrophages and enhances immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30190370 DOI: 10.1158/1078-0432.Ccr-18-0980 |
0.432 |
|
| 2018 |
Hashimoto A, Gao C, Mastio J, Kossenkov A, Abrams SI, Purandare AV, Desilva H, Wee S, Hunt JT, Jure-Kunkel M, Gabrilovich DI. Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice. Cancer Research. PMID 30139814 DOI: 10.1158/0008-5472.Can-18-1229 |
0.455 |
|
| 2018 |
Burkard-Mandel L, O'Neill R, Colligan S, Seshadri M, Abrams SI. Tumor-derived thymic stromal lymphopoietin enhances lung metastasis through an alveolar macrophage-dependent mechanism. Oncoimmunology. 7: e1419115. PMID 29721367 DOI: 10.1080/2162402X.2017.1419115 |
0.455 |
|
| 2017 |
Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, Liu H, Kokolus KM, Eng JW, Messmer MN, Attwood K, Abrams SI, Hylander BL, Repasky EA. β-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy. Cancer Research. PMID 28819022 DOI: 10.1158/0008-5472.Can-17-0546 |
0.471 |
|
| 2017 |
Singh AK, Winslow TB, Habiby Kermany M, Goritz V, Heit L, Miller A, Hoffend NC, Stein LC, Kumaraswamy L, Warren GW, Bshara W, Odunsi K, Matsuzaki J, Abrams SI, Schwaab T, et al. A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28630212 DOI: 10.1158/1078-0432.Ccr-16-2946 |
0.484 |
|
| 2017 |
Mayor PC, Eng KH, Singel KL, Abrams SI, Odunsi K, Moysich KB, Fuleihan R, Garabedian E, Lugar P, Ochs HD, Bonilla FA, Buckley RH, Sullivan KE, Ballas ZK, Cunningham-Rundles C, et al. Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. The Journal of Allergy and Clinical Immunology. PMID 28606585 DOI: 10.1016/J.Jaci.2017.05.024 |
0.314 |
|
| 2017 |
Abrams SI. Editorial: The rebirth of myeloid-derived suppressor cells: from adversary in cancer to ally in reproductive health. Journal of Leukocyte Biology. 101: 1079. PMID 28468987 DOI: 10.1189/Jlb.1Ce1216-525R |
0.327 |
|
| 2017 |
Netherby CS, Messmer MN, Burkard-Mandel L, Colligan S, Miller A, Cortes Gomez E, Wang J, Nemeth MJ, Abrams SI. The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production. Journal of Immunology (Baltimore, Md. : 1950). PMID 28356386 DOI: 10.4049/Jimmunol.1601722 |
0.527 |
|
| 2017 |
Twum DY, Burkard-Mandel L, Abrams SI. The Dr. Jekyll and Mr. Hyde complexity of the macrophage response in disease. Journal of Leukocyte Biology. PMID 28319464 DOI: 10.1189/Jlb.4Mr1116-479R |
0.329 |
|
| 2017 |
Netherby CS, Abrams SI. Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease. Cancer Immunology, Immunotherapy : Cii. PMID 28224211 DOI: 10.1007/S00262-017-1963-5 |
0.562 |
|
| 2016 |
Ku AW, Muhitch JB, Powers CA, Diehl MG, Kim M, Fisher DT, Sharda AP, Clements VK, O'Loughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, ... ... Abrams SI, et al. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. Elife. 5. PMID 27929373 DOI: 10.7554/Elife.17375 |
0.451 |
|
| 2016 |
Mammadova-Bach E, Zigrino P, Brucker C, Bourdon C, Freund M, De Arcangelis A, Abrams SI, Orend G, Gachet C, Mangin PH. Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9. Jci Insight. 1: e88245. PMID 27699237 DOI: 10.1172/Jci.Insight.88245 |
0.441 |
|
| 2016 |
Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph J, Mayor P, Abrams SI, Segal B, Wallace PK, et al. No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27677730 DOI: 10.1158/1055-9965.Epi-16-0631 |
0.411 |
|
| 2016 |
Minderman H, Maguire O, O'Loughlin KL, Muhitch J, Wallace PK, Abrams SI. Total cellular protein presence of the transcription factor IRF8 does not necessarily correlate with its nuclear presence. Methods (San Diego, Calif.). PMID 27582125 DOI: 10.1016/J.Ymeth.2016.08.011 |
0.318 |
|
| 2016 |
Abrams SI, Netherby CS, Twum DY, Messmer MN. Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 36: 442-53. PMID 27379866 DOI: 10.1089/Jir.2015.0174 |
0.549 |
|
| 2016 |
Eng JW, Mace TA, Sharma R, Twum DY, Peng P, Gibbs JF, Pitoniak R, Reed CB, Abrams SI, Repasky EA, Hylander BL. Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. Journal For Immunotherapy of Cancer. 4: 33. PMID 27330806 DOI: 10.1186/S40425-016-0136-Y |
0.454 |
|
| 2016 |
Ellis L, Ku S, Li Q, Azabdaftari G, Seliski J, Olson B, Netherby CS, Tang DG, Abrams SI, Goodrich DW, Pili R. Generation of a C57BL/6 MYC-driven mouse model and cell line of prostate cancer. The Prostate. PMID 27225803 DOI: 10.1002/Pros.23206 |
0.329 |
|
| 2016 |
Brackett CM, Kojouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO, Abrams SI, Gudkov AV. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proceedings of the National Academy of Sciences of the United States of America. PMID 26831100 DOI: 10.1073/Pnas.1521359113 |
0.49 |
|
| 2016 |
Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, Sharda AP, Clements VK, O'Loughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, ... ... Abrams SI, et al. Author response: Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes Elife. DOI: 10.7554/Elife.17375.028 |
0.372 |
|
| 2016 |
Mayor P, Eng KH, Singel KL, Abrams SI, Moysich KB, Odunsi K, Cunningham-Rundles C, Segal BH. Cancer in primary immunodeficiency diseases: An analysis of cancer incidence in the United States immune deficiency network (USIDNET) registry. Journal of Clinical Oncology. 34: 1520-1520. DOI: 10.1200/Jco.2016.34.15_Suppl.1520 |
0.31 |
|
| 2016 |
Netherby CS, Messmer MN, Abrams SI. Abstract 3249: Regulation of interferon regulatory factor-8 (IRF8) during myelopoiesis is a critical checkpoint for the formation of defective myeloid cells in cancer Cancer Research. 76: 3249-3249. DOI: 10.1158/1538-7445.Am2016-3249 |
0.542 |
|
| 2015 |
Banik D, Netherby CS, Bogner PN, Abrams SI. MMP3-mediated tumor progression is controlled transcriptionally by a novel IRF8-MMP3 interaction. Oncotarget. 6: 15164-79. PMID 26008967 DOI: 10.18632/Oncotarget.3897 |
0.418 |
|
| 2015 |
Khan AN, Kolomeyevskaya N, Singel KL, Grimm MJ, Moysich KB, Daudi S, Grzankowski KS, Lele S, Ylagan L, Webster GA, Abrams SI, Odunsi K, Segal BH. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. Oncotarget. 6: 11310-26. PMID 25888637 DOI: 10.18632/Oncotarget.3597 |
0.563 |
|
| 2015 |
Paschall AV, Zhang R, Qi CF, Bardhan K, Peng L, Lu G, Yang J, Merad M, McGaha T, Zhou G, Mellor A, Abrams SI, Morse HC, Ozato K, Xiong H, et al. IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation. Journal of Immunology (Baltimore, Md. : 1950). 194: 2369-79. PMID 25646302 DOI: 10.4049/Jimmunol.1402412 |
0.465 |
|
| 2015 |
Messmer MN, Netherby CS, Banik D, Abrams SI. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunology, Immunotherapy : Cii. 64: 1-13. PMID 25432147 DOI: 10.1007/S00262-014-1639-3 |
0.461 |
|
| 2015 |
Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunology Research. 3: 136-48. PMID 25370534 DOI: 10.1158/2326-6066.Cir-14-0036 |
0.578 |
|
| 2015 |
Paschall A, Zhang R, Bardhan K, Qi C, Peng L, Lu G, Yang J, Merad M, Zimmerman M, McGaha T, Zhou G, Mellor A, Abrams SI, Morse H, Ozato K, et al. Abstract PR05: IRF8 regulates GM-CSF expression in T cells and tumor cells to mediate myeloid-derived suppressor cell differentiation Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-Pr05 |
0.523 |
|
| 2014 |
Manjili MH, Wang XY, Abrams S. Evolution of Our Understanding of Myeloid Regulatory Cells: From MDSCs to Mregs. Frontiers in Immunology. 5: 303. PMID 25071764 DOI: 10.3389/Fimmu.2014.00303 |
0.398 |
|
| 2014 |
Messmer MN, Kokolus KM, Eng JW, Abrams SI, Repasky EA. Mild cold-stress depresses immune responses: Implications for cancer models involving laboratory mice. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 36: 884-91. PMID 25066924 DOI: 10.1002/Bies.201400066 |
0.426 |
|
| 2014 |
Verbrugge I, Gasparini A, Haynes NM, Hagekyriakou J, Galli M, Stewart TJ, Abrams SI, Yagita H, Verheij M, Johnstone RW, Borst J, Neefjes J. The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling. Radiation Research. 182: 219-29. PMID 24960417 DOI: 10.1667/Rr13511.1 |
0.479 |
|
| 2014 |
Waight JD, Banik D, Griffiths EA, Nemeth MJ, Abrams SI. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. The Journal of Biological Chemistry. 289: 15642-52. PMID 24753251 DOI: 10.1074/Jbc.M113.544320 |
0.711 |
|
| 2014 |
Farren MR, Carlson LM, Netherby CS, Lindner I, Li PK, Gabrilovich DI, Abrams SI, Lee KP. Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance. Science Signaling. 7: ra16. PMID 24550541 DOI: 10.1126/Scisignal.2004656 |
0.52 |
|
| 2014 |
Kolomeyevskaya N, Khan N, Dolnick R, Abrams S, Odunsi K, Lele S, Segal B. Cytokine profiling of ascites identifies macrophage inflammatory protein-beta and tumor necrosis factor–alpha as predictors of progression-free survival in patients with epithelial ovarian cancer Gynecologic Oncology. 133: 113. DOI: 10.1016/J.Ygyno.2014.03.300 |
0.387 |
|
| 2014 |
Kolomeyevskaya N, Khan N, Grimm M, Singel K, Grzankowski K, Abrams S, Odunsi K, Segal B. Targeting myeloid cells in the tumor microenvironment as a strategy to enhance vaccine efficacy in epithelial ovarian cancer Gynecologic Oncology. 133: 113. DOI: 10.1016/J.Ygyno.2014.03.299 |
0.446 |
|
| 2014 |
Paluch B, Srivastava P, Abrams S, Wetzler M, Griffiths E. Exposure to Decitabine (Dac), Both In Vitro and in Peripheral Blood Blasts From Acute Myeloid Leukemia (AML) Patients, Enhances the Expression of CD58 and Antigen Presentation Machinery on Leukemic Cells Clinical Lymphoma, Myeloma & Leukemia. 14. DOI: 10.1016/J.Clml.2014.06.048 |
0.335 |
|
| 2013 |
Kokolus KM, Capitano ML, Lee CT, Eng JW, Waight JD, Hylander BL, Sexton S, Hong CC, Gordon CJ, Abrams SI, Repasky EA. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proceedings of the National Academy of Sciences of the United States of America. 110: 20176-81. PMID 24248371 DOI: 10.1073/Pnas.1304291110 |
0.745 |
|
| 2013 |
Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, Bogner PN, Farren MR, Lee KP, Liu K, Abrams SI. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. The Journal of Clinical Investigation. 123: 4464-78. PMID 24091328 DOI: 10.1172/Jci68189 |
0.767 |
|
| 2013 |
Godoy HE, Khan AN, Vethanayagam RR, Grimm MJ, Singel KL, Kolomeyevskaya N, Sexton KJ, Parameswaran A, Abrams SI, Odunsi K, Segal BH. Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice. Plos One. 8: e69631. PMID 23922763 DOI: 10.1371/Journal.Pone.0069631 |
0.553 |
|
| 2013 |
Hu X, Bardhan K, Paschall AV, Yang D, Waller JL, Park MA, Nayak-Kapoor A, Samuel TA, Abrams SI, Liu K. Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer. The Journal of Biological Chemistry. 288: 19103-15. PMID 23677993 DOI: 10.1074/Jbc.M112.434530 |
0.545 |
|
| 2013 |
Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proceedings of the National Academy of Sciences of the United States of America. 110: E1291-300. PMID 23509246 DOI: 10.1073/Pnas.1220580110 |
0.525 |
|
| 2013 |
Kokolus KM, Capitano ML, Eng JW, Hylander BL, Gordon CJ, Abrams SI, Repasky EA. The impact of metabolic stress on anti-tumor immunity in laboratory mice Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P122 |
0.48 |
|
| 2013 |
Spangler H, Farren MR, Carlson LM, Abrams S, Lee KP. Progenitor Cell Differentiation Into Dendritic Cells Requires Cytokine Mediated PKC-IRF Relationships Blood. 122: 2449-2449. DOI: 10.1182/Blood.V122.21.2449.2449 |
0.415 |
|
| 2013 |
Janda G, Abrams S, Habiby M, Romano M, Hoffmeyer J, Warren G, Schwaab T. 165 IRRADIATION OF RENAL CELL CARINOMA IN MURINE XENOGRAFT ATTENUATES TUMOR GROWTH AND MODULATES ANTITUMOR IMMUNE RESPONSE Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1545 |
0.51 |
|
| 2013 |
Janda G, Abrams S, Habiby M, Romano M, Hoffmeyer J, Warren G, Schwaab T. 164 IRRADIATION OF RENAL CELL CARCINOMA CELL LINES INCREASES THEIR IMMUNOGENICITY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1544 |
0.303 |
|
| 2012 |
Banik D, Khan AN, Walseng E, Segal BH, Abrams SI. Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity. Plos One. 7: e45422. PMID 23028998 DOI: 10.1371/Journal.Pone.0045422 |
0.528 |
|
| 2012 |
Abrams SI, Waight JD. Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression. Oncoimmunology. 1: 550-551. PMID 22754783 DOI: 10.4161/Onci.19334 |
0.76 |
|
| 2011 |
Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. Plos One. 6: e27690. PMID 22110722 DOI: 10.1371/Journal.Pone.0027690 |
0.756 |
|
| 2010 |
Zimmerman M, Yang D, Hu X, Liu F, Singh N, Browning D, Ganapathy V, Chandler P, Choubey D, Abrams SI, Liu K. IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells. Plos One. 5: e14076. PMID 21124930 DOI: 10.1371/Journal.Pone.0014076 |
0.514 |
|
| 2010 |
Abrams SI. A multi-functional role of interferon regulatory factor-8 in solid tumor and myeloid cell biology. Immunologic Research. 46: 59-71. PMID 19756408 DOI: 10.1007/S12026-009-8125-6 |
0.54 |
|
| 2009 |
Stewart TJ, Greeneltch KM, Reid JE, Liewehr DJ, Steinberg SM, Liu K, Abrams SI. Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells. Journal of Cellular and Molecular Medicine. 13: 3939-50. PMID 20196788 DOI: 10.1111/J.1582-4934.2009.00685.X |
0.432 |
|
| 2009 |
Stewart TJ, Liewehr DJ, Steinberg SM, Greeneltch KM, Abrams SI. Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells. Journal of Immunology (Baltimore, Md. : 1950). 183: 117-28. PMID 19542426 DOI: 10.4049/Jimmunol.0804132 |
0.575 |
|
| 2008 |
Stewart TJ, Abrams SI. How tumours escape mass destruction Oncogene. 27: 5894-5903. PMID 18836470 DOI: 10.1038/Onc.2008.268 |
0.374 |
|
| 2008 |
Stewart TJ, Lutsiak ME, Abrams SI. Immune consequences of protracted host-tumor interactions in a transgenic mouse model of mammary carcinoma. Cancer Investigation. 26: 237-49. PMID 18317964 DOI: 10.1080/07357900701708419 |
0.552 |
|
| 2008 |
Yang D, Stewart TJ, Smith KK, Georgi D, Abrams SI, Liu K. Downregulation of IFN-gammaR in association with loss of Fas function is linked to tumor progression. International Journal of Cancer. Journal International Du Cancer. 122: 350-62. PMID 17918178 DOI: 10.1002/Ijc.23090 |
0.547 |
|
| 2007 |
Greeneltch KM, Schneider M, Steinberg SM, Liewehr DJ, Stewart TJ, Liu K, Abrams SI. Host immunosurveillance controls tumor growth via IFN regulatory factor-8 dependent mechanisms. Cancer Research. 67: 10406-16. PMID 17974984 DOI: 10.1158/0008-5472.Can-07-1228 |
0.57 |
|
| 2007 |
Yang D, Ud Din N, Browning DD, Abrams SI, Liu K. Targeting lymphotoxin beta receptor with tumor-specific T lymphocytes for tumor regression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5202-10. PMID 17785576 DOI: 10.1158/1078-0432.Ccr-07-1161 |
0.532 |
|
| 2007 |
Stewart TJ, Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. Journal of Immunology (Baltimore, Md. : 1950). 179: 2851-9. PMID 17709499 DOI: 10.4049/Jimmunol.179.5.2851 |
0.541 |
|
| 2007 |
Yang D, Thangaraju M, Greeneltch K, Browning DD, Schoenlein PV, Tamura T, Ozato K, Ganapathy V, Abrams SI, Liu K. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Research. 67: 3301-9. PMID 17409439 DOI: 10.1158/0008-5472.Can-06-4068 |
0.527 |
|
| 2007 |
Stewart TJ, Greeneltch KM, Lutsiak ME, Abrams SI. Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. Expert Reviews in Molecular Medicine. 9: 1-20. PMID 17284328 DOI: 10.1017/S1462399407000233 |
0.349 |
|
| 2006 |
Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, Chen JF, Jackson EK, Apasov S, Abrams S, Sitkovsky M. A2A adenosine receptor protects tumors from antitumor T cells. Proceedings of the National Academy of Sciences of the United States of America. 103: 13132-7. PMID 16916931 DOI: 10.1073/Pnas.0605251103 |
0.528 |
|
| 2006 |
Palena C, Abrams SI, Schlom J, Hodge JW. Cancer vaccines: preclinical studies and novel strategies. Advances in Cancer Research. 95: 115-45. PMID 16860657 DOI: 10.1016/S0065-230X(06)95004-0 |
0.331 |
|
| 2006 |
Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, Childs R. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Research. 66: 7317-25. PMID 16849582 DOI: 10.1158/0008-5472.Can-06-0680 |
0.525 |
|
| 2006 |
Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1897-905. PMID 16551875 DOI: 10.1158/1078-0432.Ccr-05-1761 |
0.392 |
|
| 2006 |
Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. Journal of Immunology (Baltimore, Md. : 1950). 176: 3374-82. PMID 16517705 DOI: 10.4049/Jimmunol.176.6.3374 |
0.547 |
|
| 2006 |
Lundqvist A, Greeneltch K, Berg M, Srivastava S, Harashima N, Yokoyama H, Smith A, Abrams S, Childs R. In Vitro and In Vivo Sensitization of Malignant Cells to Autologous Natural Killer Cell Cytotoxicity Following Exposure to Bortezomib. Blood. 108: 925-925. DOI: 10.1182/Blood.V108.11.925.925 |
0.517 |
|
| 2005 |
Nesterova MV, Johnson NR, Stewart T, Abrams S, Cho-Chung YS. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5950-5. PMID 16115938 DOI: 10.1158/1078-0432.Ccr-05-0624 |
0.356 |
|
| 2005 |
Liu K, Caldwell SA, Abrams SI. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Cancer Research. 65: 4376-88. PMID 15899830 DOI: 10.1158/0008-5472.Can-04-4269 |
0.496 |
|
| 2005 |
Liu K, Caldwell SA, Abrams SI. Cooperative disengagement of Fas and intercellular adhesion molecule-1 function in neoplastic cells confers enhanced colonization efficiency. Cancer Research. 65: 1045-54. PMID 15705906 |
0.398 |
|
| 2005 |
Abrams SI. Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response. Frontiers in Bioscience : a Journal and Virtual Library. 10: 809-21. PMID 15569621 DOI: 10.2741/1575 |
0.52 |
|
| 2004 |
Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Research. 64: 4328-37. PMID 15205348 DOI: 10.1158/0008-5472.Can-04-0073 |
0.512 |
|
| 2004 |
Abrams SI. Regulation of tumor progression by anti-neoplastic T cell responses. Cancer Biology & Therapy. 3: 140-6. PMID 14739786 DOI: 10.4161/Cbt.3.2.758 |
0.554 |
|
| 2003 |
Liu K, McDuffie E, Abrams SI. Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations. Journal of Immunology (Baltimore, Md. : 1950). 171: 4164-74. PMID 14530339 DOI: 10.4049/Jimmunol.171.8.4164 |
0.465 |
|
| 2003 |
Lindinger P, Mostböck S, Hammerl P, Hartl A, Thalhamer J, Abrams SI. Induction of murine ras oncogene peptide-specific T cell responses by immunization with plasmid DNA-based minigene vectors. Vaccine. 21: 4285-96. PMID 14505911 DOI: 10.1016/S0264-410X(03)00486-9 |
0.393 |
|
| 2003 |
Caldwell SA, Ryan MH, McDuffie E, Abrams SI. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. Journal of Immunology (Baltimore, Md. : 1950). 171: 2402-12. PMID 12928387 DOI: 10.4049/Jimmunol.171.5.2402 |
0.504 |
|
| 2003 |
Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 170: 6338-47. PMID 12794167 DOI: 10.4049/Jimmunol.170.12.6338 |
0.531 |
|
| 2003 |
Liu K, Abrams SI. Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-gamma. Journal of Immunology (Baltimore, Md. : 1950). 170: 6329-37. PMID 12794166 DOI: 10.4049/Jimmunol.170.12.6329 |
0.424 |
|
| 2003 |
Liu K, Abrams SI. Alterations in Fas expression are characteristic of, but not solely responsible for, enhanced metastatic competence. Journal of Immunology (Baltimore, Md. : 1950). 170: 5973-80. PMID 12794124 DOI: 10.4049/Jimmunol.170.12.5973 |
0.442 |
|
| 2002 |
Bergmann-Leitner ES, Abrams SI. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunology, Immunotherapy : Cii. 50: 445-55. PMID 11761438 DOI: 10.1007/S002620100229 |
0.485 |
|
| 2001 |
Ryan MH, Bristol JA, McDuffie E, Abrams SI. Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope. Journal of Immunology (Baltimore, Md. : 1950). 167: 4286-92. PMID 11591751 DOI: 10.4049/Jimmunol.167.8.4286 |
0.516 |
|
| 2001 |
Bergmann-Leitner ES, Abrams SI. Positive and negative consequences of soluble Fas ligand produced by an antigen-specific CD4(+) T cell response in human carcinoma immune interactions. Cellular Immunology. 209: 49-62. PMID 11414736 DOI: 10.1006/Cimm.2001.1781 |
0.463 |
|
| 2001 |
Alper Ö, Bergmann-Leitner ES, Abrams S, Cho-Chung YS. Apoptosis, growth arrest and suppression of invasiveness by CRE-decoy oligonucleotide in ovarian cancer cells: Protein kinase A downregulation and cytoplasmic export of CRE-binding proteins Molecular and Cellular Biochemistry. 218: 55-63. PMID 11330838 DOI: 10.1023/A:1007205205131 |
0.392 |
|
| 2001 |
Ryan MH, Abrams SI. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant. Cancer Immunology, Immunotherapy. 49: 603-612. PMID 11225991 DOI: 10.1007/S002620000156 |
0.499 |
|
| 2000 |
Bristol JA, Orsini C, Lindinger P, Thalhamer J, Abrams SI. Identification of a ras oncogene peptide that contains both CD4+ and CD8+ T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization Cellular Immunology. 205: 73-83. PMID 11104579 DOI: 10.1006/Cimm.2000.1712 |
0.395 |
|
| 2000 |
Bergmann-Leitner ES, Abrams SI. Influence of interferon gamma on modulation of Fas expression by human colon carcinoma cells and their subsequent sensitivity to antigen-specific CD8+ cytotoxic T lymphocyte attack. Cancer Immunology, Immunotherapy : Cii. 49: 193-207. PMID 10941902 DOI: 10.1007/S002620000105 |
0.459 |
|
| 2000 |
Bergmann-Leitner ES, Abrams SI. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL. Journal of Immunology (Baltimore, Md. : 1950). 164: 4941-54. PMID 10779805 DOI: 10.4049/Jimmunol.164.9.4941 |
0.427 |
|
| 2000 |
Abrams SI, Schlom J. Rational antigen modification as a strategy to upregulate or downregulate antigen recognition. Current Opinion in Immunology. 12: 85-91. PMID 10679405 DOI: 10.1016/S0952-7915(99)00055-2 |
0.39 |
|
| 1999 |
Bristol JA, Schlom J, Abrams SI. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer. Cellular Immunology. 194: 78-89. PMID 10357883 DOI: 10.1006/Cimm.1999.1489 |
0.396 |
|
| 1999 |
Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra CJ, Schlom J. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 22: 155-65. PMID 10093040 DOI: 10.1097/00002371-199903000-00007 |
0.426 |
|
| 1998 |
Schlom J, Tsang KY, Kantor JA, Abrams SI, Zaremba S, Greiner J, Hodge JW. Cancer vaccine development. Expert Opinion On Investigational Drugs. 7: 1439-52. PMID 15992042 DOI: 10.1517/13543784.7.9.1439 |
0.365 |
|
| 1997 |
Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cellular Immunology. 182: 137-51. PMID 9514698 DOI: 10.1006/Cimm.1997.1224 |
0.418 |
|
| 1997 |
McLaughlin JP, Abrams S, Kantor J, Dobrzanski MJ, Greenbaum J, Schlom J, Greiner JW. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocytemacrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity Journal of Immunotherapy. 20: 449-459. PMID 9409450 DOI: 10.1097/00002371-199711000-00004 |
0.552 |
|
| 1997 |
Uzendoski K, Kantor JA, Abrams SI, Schlom J, Hodge JW. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: Induction and potentiation of antitumor responses Human Gene Therapy. 8: 851-860. PMID 9143911 DOI: 10.1089/Hum.1997.8.7-851 |
0.501 |
|
| 1997 |
Abrams SI, Hodge JW, McLaughlin JP, Steinberg SM, Kantor JA, Schlom J. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine Journal of Immunotherapy. 20: 48-59. PMID 9101413 DOI: 10.1097/00002371-199701000-00005 |
0.418 |
|
| 1996 |
Schott ME, Wells DT, Schlom J, Abrams SI. Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens Cellular Immunology. 174: 199-209. PMID 8954620 DOI: 10.1006/Cimm.1996.0310 |
0.337 |
|
| 1996 |
Schlom J, Kantor J, Abrams S, Tsang KY, Panicali D, Hamilton JM. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Breast Cancer Research and Treatment. 38: 27-39. PMID 8825120 DOI: 10.1007/Bf01803781 |
0.44 |
|
| 1996 |
Abrams SI, Stanziale SF, Lunin SD, Zaremba S, Schlom J. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. European Journal of Immunology. 26: 435-43. PMID 8617315 DOI: 10.1002/Eji.1830260225 |
0.379 |
|
| 1996 |
Bergmann-Leitner ES, Schlom J, Abrams SI. HUMAN HLA-A2-RESTRICTED, CD8+ CYTOTOXIC T-CELLS RECOGNIZE AND LYSE TUMOR CELLS ENDOGENOUSLY EXPRESSING A K-RAS POINT MUTATION AT CODON 12 Journal of Immunotherapy. 19: 459. DOI: 10.1097/00002371-199611000-00024 |
0.412 |
|
| 1996 |
Abrams SI, Khleif SN, Bergmann-Leitner ES, Schlom J. PRODUCTION OF CD4+ AND CD8+ T CELL LINES FROM PATIENTS VACCINATED WITH MUTATED RAS PEPTIDES Journal of Immunotherapy. 19: 459. DOI: 10.1097/00002371-199611000-00023 |
0.316 |
|
| 1995 |
Bei R, Kantor J, Kashmiri SV, Abrams S, Schlom J. Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 16: 275-82. PMID 7881636 DOI: 10.1097/00002371-199411000-00003 |
0.449 |
|
| 1995 |
Abrams SI, Dobrzanski MJ, Wells DT, Stanziale SF, Zaremba S, Masuelli L, Kantor JA, Schlom J, Masuelle L [corrected to Masuelli L]. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. European Journal of Immunology. 25: 2588-97. PMID 7589131 DOI: 10.1002/Eji.1830250928 |
0.447 |
|
| 1995 |
Khleif SN, Abrams S, Allegra C, Chen A, Chung Y, Hamilton JM, Kohler DR, Schlom J. A PHASE I TRIAL OF VACCINE THERAPY WITH TUMOR SPECIFIC MUTATED RAS PEPTIDES ADMINISTERED SUBCUTANEOUSLY IN CANCER PATIENTS Journal of Immunotherapy. 18: 134. DOI: 10.1097/00002371-199508000-00036 |
0.359 |
|
| 1994 |
Abrams S, Wells D, Kantor J, Schlom J. CYTOTOXIC ACTIVITY BY PEPTIDE-INDUCED CD4+ T-LYMPHOCYTES AGAINST TUMOR CELLS EXPRESSING POINT-MUTATED Ki-RAS Journal of Immunotherapy. 16: 234. DOI: 10.1097/00002371-199410000-00009 |
0.433 |
|
| 1992 |
Kantor J, Irvine K, Abrams S, Kaufman H, Dipietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine Journal of the National Cancer Institute. 84: 1084-1091. PMID 1619682 DOI: 10.1093/Jnci/84.14.1084 |
0.456 |
|
| Show low-probability matches. |